

Technology Appraisal Committee Meeting (Committee A)

Minutes: Unconfirmed

Date and Time: Tuesday 19th January 2016, 10.00am – 2.00pm

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

Present:	1. Dr Jane Adam (Chair)	Present for all notes
	2. Professor Iain Squire (Vice-Chair)	Present for all notes
	3. Dr Mohit Misra	Present for all notes
	4. Dr Jeremy Braybrooke	Present for all notes
	5. Dr Gerardine Bryant	Present for all notes
	6. Dr Nerys Woolacott	Present for all notes
	7. Dr Brian Shine	Present for all notes
	8. Mr David Thomson	Present for all notes
	9. Dr Justin Daniels	Present for all notes
	10. Dr Andrew England	Present for all notes
	11. Dr Paul Robinson	Present for all notes
	12. Dr Graham Ash	Present for all notes
	13. Mr Stephen Sharp	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Bijal Joshi	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Zoe Charles	Technical Adviser, National Institute for Health and Care Excellence	Present for all notes

Non-public observers:

Joshua South	Coordinator, National Institute for Health and Care Excellence	Present for notes all notes
Ria Skelton	Editor, National Institute for Health and Care Excellence	Present for notes all notes
Dr Rosie Benneyworth	Non-Executive member, National Institute for Health and Care Excellence	Present for notes all notes
Dr Rachel Squires	Fellow, National Institute	Present for notes all notes

Jeremy Powell

for Health and Care
Excellence
Project Manager, National
Institute for Health and
Care Excellence

Present for notes all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468].
2. Apologies were received from Professor John McMurray, Mrs Pamela Rees, Professor Aileen Clarke, Dr Rachel Hobson, Dr Anne McCune, Professor Olivia Wu, Ms Ellen Rule, Mrs Sarah Parry, and Dr John Watkins.

Any other Business

3. None

Notes from the last meeting

4. The minutes were agreed.

Appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468]

Part 1 – Open session

5. The Chair welcomed the invited experts: Dr Steve Edwards and Ms Samantha Barton to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from PharmaMar to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Jane Adam, Professor Iain Squire, Dr Mohit Misra, Dr Jeremy Braybrooke, Dr Gerardine Bryant, Dr Nerys Woolacott, Dr Brian Shine, Mr David Thomson, Dr Justin Daniels, Dr Andrew England, Dr Paul Robinson, Dr Graham Ash, and Mr Stephen Sharp all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468].
 - 7.2. Mr Adrian Griffin declared a non-personal specific financial interest as he is employed by Johnson and Johnson whom are a comparator company in the appraisal.
 - 7.2.1 It was agreed that this declaration would prevent Dr Adrian Griffin from participating in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.

- 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468]
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468]
10. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
11. The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468] on the basis of the evidence before them.
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. The Committee continued to discuss the clinical and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [ID468].
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

17. Tuesday 16th February 2016, from 10.0am – 5.00pm at Prospero House, 241 Borough High Street, London SE1 1GA.